











56Outcomes With As-Needed Aflibercept and
Macular Laser Following the Phase III VISTA
DME Trial: ENDURANCE 12-Month Extension
StudyCHARLES C. WYKOFF, RYAN T. LE, RAHUL N. KHURANA, DAVID M. BROWN, WILLIAM C. OU, RUI WANG,
W. LLOYD CLARK, AND DAVID S. BOYER, ON BEHALF OF THE ENDURANCE STUDY GROUP PURPOSE: To determine whether the efficacy and
safety achieved with 2.0 mg intravitreal aflibercept injec-
tions (IAIs) for diabetic macular edema (DME) during
the phase III VISTA DME trial were maintained with
individualized, as-needed treatment.
 DESIGN: Phase IV, multicenter, open-label extension
study.
 METHODS: Sixty patients completing VISTA DME
elected to enter the ENDURANCE extension study.
All patients received IAIs in the presence of clinically
relevant DME. Patients were observed at 4-, 8-, or 12-
week intervals depending on the need for treatment.
Main outcome measures were mean IAIs given through
month 12 (M12), the proportion of patients receiving
no IAIs, and the role of macular laser in decreasing treat-
ment burden among patients requiring ongoing IAIs.
 RESULTS: A mean of 4.5 IAIs were administered
through M12. Eighteen (30%) patients required no
IAIs, and among those who met IAI retreatment criteria,
a mean of 6.0 IAIs were administered throughM12. Best-
corrected visual acuity gains achieved during VISTA
DME were maintained and stable with individualized
dosing during ENDURANCE, fluctuating by <1.5
mean letters from the baseline at all time points. Likewise,
mean central retinal thickness remained relatively stable
during ENDURANCE. Thirty-seven (62%) patients
met macular laser criteria at a mean of 19.5 weeks with
no significant difference in the frequency of IAIs before
or after macular laser.
 CONCLUSION: Vision gains achieved during the 3-year
VISTA DME trial were maintained through M12 of the
ENDURANCE extension study with a reduced treat-
ment frequency, with 30% of patients receiving noupplemental Material available at AJO.com.
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D
IABETIC MACULAR EDEMA (DME) IS A MAJOR
cause of vision loss, with an increasing prevalence
attributable to the worldwide diabetes mellitus
epidemic.1,2 Currently, 4 intravitreally administered
pharmacologic agents are approved by the U.S. Food and
Drug Administration for the treatment of DME.
Ranibizumab (Lucentis; Genentech, South San
Francisco, CA)3,4 and aflibercept (Eylea; Regeneron
Pharmaceuticals, Inc, Tarrytown, NY)5,6 are both
protein-based medications that block the activity of
vascular endothelial growth factor A (VEGF), a key cyto-
kine in the pathophysiology of diabetic retinopathy (DR)
and DME that increases vascular permeability and stimu-
lates angiogenesis.7,8
VEGF blockade has proven remarkably effective in
several phase III study programs at reducing DME and
improving visual acuity (VA) in eyes with center-
involved DME causing VA loss.3,5,9,10 In the VISTA
DME (Study of Intravitreal Aflibercept Injection in
Patients With Diabetic Macular Edema) and VIVID
DME (Intravitreal Aflibercept Injection in Vision
Impairment Due to DME) phase III trials, patients were
randomized to either macular laser or 2.0 mg intravitreal
aflibercept injections (IAIs) given either monthly or
every other month after 5 monthly doses. IAIs led to
rapid and sustained VA and anatomic improvement
compared to macular laser.5
After an initial period of intensive anti-VEGF therapy,
several analyses of patients with DME have suggested
that less frequent anti-VEGF dosing may be effective at
maintaining visual and anatomic gains in most patients.
For example, the RESTORE (12 Month Core Study to
Assess the Efficacy and Safety of Ranibizumab (Intravitreal
Injections) in Patients With Visual Impairment Due to
Diabetic Macular Edema and a 24 Month Open-label0002-9394
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Extension Study),11 Diabetic Retinopathy Clinical
Research Network (DRCR.Net) Protocol I,12 and OLE
(open-label extension)13 studies have reported that mean
VA gains obtained with initial monthly ranibizumab
dosing were maintained with a substantial reduction in
treatment burden using protocol-specified retreatment al-
gorithms. All such analyses have used ranibizumab treat-
ments, and no prospective data have been reported on
the use of IAIs for DME management beyond the 3-year
VISTA DME phase III trial endpoint.
While anti-VEGF therapy leads to robust mean VA and
anatomic improvements in DME management, many
eyes demonstrate persistent DME despite aggressive ther-
apy. For example, in the DRCR.Net Protocol T study, be-
tween 41–64% of patients met prespecified criteria for
macular laser attributable to persistent DME causing VA
loss.14 In this context, macular laser15 may be valuable in
optimizing outcomes and reducing ongoing treatment
burden. For example, through 5 years of follow-up in the
DRCR.Net Protocol I study, application of macular laser
at the initiation of intravitreal ranibizumab treatment
appeared to lead to a reduction in retreatment frequency.12
The ENDURANCE (Long-Term Efficacy and Safety of
Intravitreal Aflibercept for the Treatment of DME in Sub-
jects Who Completed the VISTA DME Trial) extension
study was designed to evaluate both the ability of an indi-
vidualized IAI retreatment approach to maintain the ben-
efits achieved with IAIs during the VISTA DME trial and
the ability of macular laser to decrease treatment burden
among patients requiring ongoing IAIs.METHODS
THE ENDURANCE EXTENSION STUDY IS A PHASE IV, OPEN-
label study (clinicaltrials.gov identifier NCT02299336)
that assesses the need for ongoing IAIs following the 3-
year, randomized, phase III VISTA DME trial.5,6 Of the
357 patients who completed VISTA DME,16 all of the pa-
tients at 4 major clinical sites (n¼ 89) were offered the op-
portunity to enroll in ENDURANCE. Data were collected
at Retina Consultants of Houston (n ¼ 26; Houston, Katy,
and Woodlands, TX), Palmetto Retina Center (n ¼ 16;
West Columbia, SC), Northern California Retina Vitreous
Associates (n ¼ 9; Mountain View, CA), and Retina Vit-
reous Associates Medical Group (n ¼ 9; Beverly Hills,
CA). Prospective institutional review board (Sterling,
Atlanta, GA) approval was obtained for this Health Insur-
ance Portability and Accountability Act–compliant trial
adhering to the tenets of the Declaration of Helsinki, and
participants provided written informed consent.
At all visits, patients underwent Early Treatment Dia-
betic Retinopathy Study (ETDRS) best-corrected visual
acuity (BCVA) testing at 4 m, slit-lamp and dilated
ophthalmic examination, and spectral-domain opticalVOL. 173 AFLIBERCEPT IN DME: ENDUcoherence tomography (SD-OCT; Spectralis HRA.OCT,
Heidelberg Engineering, Heidelberg, Germany). The SD-
OCT acquisition protocol featured a volume scan (20 3
20, 49 lines, 768 A-scans per line) with 9-times image aver-
aging.
During ENDURANCE, patients were treated with
2.0 mg IAIs as-needed in the presence of clinically relevant
DME (CR-DME) determined by the investigator as DME
limiting optimal visual function in the context of the cur-
rent visual acuity, SD-OCT, dilated ophthalmoscopic ex-
amination findings, and fluorescein angiography (when
performed).
The interval between patient visits was individualized
based on disease activity. Initially, all patients were exam-
ined every 4 weeks (28 6 7 days). If a patient received no
IAIs at 3 consecutive 4-week visits, the interval between
visits was lengthened to 8 weeks. At this point, if the pa-
tient received no additional IAIs at 3 consecutive 8-week
visits, the interval between visits was lengthened to
12 weeks. If the patient developed recurrent CR-DME at
any time, IAI was administered and the interval between
visits was reduced to 4 weeks; at this time, the patient
restarted the extension protocol, again being required to
be evaluated without IAIs at 3 consecutive 4-week visits
before extending to an 8-week visit interval.
Beginning at week 12, patients were eligible for macular
laser if >_2 IAIs were given in <_24 weeks. After the initial
macular laser treatment, patients were eligible for macular
laser retreatment after 90 days if they again received >_2
IAIs within the previous 90 days. When eligible for macu-
lar laser, patients underwent fluorescein angiography. To
qualify for macular laser, a patient was required to show
either microaneurysms or diffuse leakage that the investi-
gator believed would benefit from treatment with macular
laser. Patients discontinued treatment with macular laser if
any of the following were present: significant macular
ischemia involving the foveal avascular zone (FAZ), if
treatment would be too close to the FAZ, or if the macular
edema was not related to DME. Targeted laser treatment
was applied to all leaking microaneurysms outside of the
FAZ, and grid laser treatment was applied to areas of diffuse
leakage and areas of retinal ischemia outside of the FAZ.
Prophylactic peri-IAI topical ophthalmic antibiotics
were not used. The use of subconjunctival anesthesia was
optional at the investigator’s discretion (ie, 2% lidocaine
without epinephrine at the injection site). After topical
anesthesia, the periocular skin, eyelids, and eyelashes
were disinfected with 10% povidone iodine swabs, and
5% povidone iodine ophthalmic solution was applied to
the ocular surface. After IAI, finger-counting testing was
performed. All patients were monitored with safety assess-
ments consisting of ocular adverse events (AEs) and serious
adverse events (SAEs). The population used for safety an-
alyses included all patients enrolled.
The accuracy of the SD-OCT automated segmentation
(ie, internal limiting membrane and Bruch’s membrane)57RANCE EXTENSION STUDY
FIGURE 1. Patient flow from VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema)
into and through ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects
Who Completed the VISTA DME Trial). Patient counts for VISTA DME arms indicate the number of patients completing week
148.16 Q4 indicates patients who were randomized to intravitreal aflibercept injections every 4 weeks during VISTA DME. Q8 in-
dicates patients who were randomized to intravitreal aflibercept injections every 8 weeks after 5 initial monthly doses during VISTA
DME. Laser indicates patients who were randomized to the macular laser photocoagulation arm during VISTA DME.
TABLE 1. Baseline Demographics of Patients in VISTA DME





Mean age, y 62.3 65.3
Female, n (%) 209 (45.5) 29 (48.3)
Race, n (%)
White 384 (83.7) 46 (76.7)
Black or African American 51 (11.1) 9 (15.0)
Asian 10 (2.2) 5 (8.3)
Mean HbA1c, % 7.8 7.5
Mean duration of diabetes, y 17.1 18.6
Mean BCVA, letters 59.3 69.6
Snellen equivalent 20/63 20/40
Mean CRT thickness, mm 482 290
BCVA ¼ best corrected visual acuity; CRT ¼ central retinal
thickness; DME ¼ diabetic macular edema; HbA1c ¼ glycated
hemoglobin.was evaluated, and segmentation errors were corrected
manually before computation of change maps and change
in central retinal thickness (CRT). Of the 6 patients
(10%) who did not complete year 1, corresponding data
are included until the date of study withdrawal. Statistical
comparisons were performed with paired Student t tests or
analysis of variance (ANOVA) using SAS software
(version 9.1.3; SAS Inc, Cary, NC) where appropriate.
Specific efficacy analyses were evaluated by prior treat-
ment group from the VISTA DME trial: 2 mg IAI every
4 weeks (Q4), 2 mg IAI every 8 weeks after 5 initial monthly
doses (Q8), or macular laser treatment (laser). The number
of patients enrolled in ENDURANCE from the original
VISTA DME arms was 21, 21, and 18 for the Q4, Q8, and
laser arms, respectively. Through 3 years of fixed IAI dosing,
the Q4 and Q8 arms achieved similar visual and anatomic
gains; therefore, outcomes during the core VISTA DME
trial among these arms were pooled. Beginning at week 24
of VISTA DME, patients randomized to laser were eligible
for criteria-based rescue treatment with IAIs if substantial
VAwas lost; data including theVAgains achievedwith sub-
sequent IAI rescue are shown for this population. Beginning
at week 100 of VISTADME, all patients randomized to laser
were eligible for criteria-based IAIs.RESULTS
SIXTY PATIENTS ENROLLED IN THE ENDURANCE EXTENSION
study between November 2014 and March 201558 AMERICAN JOURNAL OF(Figure 1). Demographics were similar to the overall
VISTA DME population, with ENDURANCE patients
demonstrating a BCVA gain of 10 ETDRS letters and
190-mm reduction in CRT compared to VISTADME base-
line because of the visual and anatomic benefits achieved
during VISTA DME (Table 1). At ENDURANCE base-
line, the mean age was 65.3 years (range 43–81 years), the
mean glycated hemoglobin was 7.5% (range 5.0–11.6%),
the mean BCVA was 69.6 ETDRS letters (approximateJANUARY 2017OPHTHALMOLOGY
FIGURE 2. Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) during
VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) and ENDURANCE (Long-
Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects Who Completed the VISTA DME Trial)
extension study. IAI indicates patients who were randomized to intravitreal aflibercept injections during VISTA DME, combining
patients in both the monthly aflibercept arm and every other month aflibercept arm after 5 monthly loading doses. Laser indicates
patients who were randomized to the macular laser photocoagulation arm during VISTA DME.Snellen equivalent 20/40), and the mean CRT was 290 mm
(range 182–591 mm). Fifty-four (90%) patients completed
month 12 (M12); 3 patients withdrew consent at baseline,
week 8, and week 12, because of a motor vehicle accident,
patient preference, and moving out of state, respectively,
while 3 were lost to follow-up. Of 666 possible visits among
all patients through M12, 29 (4%) were missed.
 VISUAL ACUITY AND ANATOMIC OUTCOMES: The
mean change in BCVA from the VISTA DME baseline
through M12 of the ENDURANCE extension study is
presented in Figure 2. Overall, BCVA outcomes were sta-
ble during ENDURANCE, fluctuating by <1.5 mean let-
ters at all ENDURANCE time points. Patients who
required no IAIs during ENDURANCE experienced a
BCVA change ofþ0.8 mean letters through M12. Patients
who received >_1 IAI experienced a BCVA change of þ0.6
mean letters over the same time period. BCVA was similar
at M12 of ENDURANCE for each of the original VISTA
DME randomized arms (P ¼ .73). After transitioning
from fixed dosing for the Q4 and Q8 arms to individualized
dosing during ENDURANCE, BCVA gains achieved at
the end of VISTA DME were maintained through M12
of the ENDURANCE extension study. Similarly, BCVA
gains achieved in the laser arm with as-needed IAIs during
year 3 of VISTA DME were maintained with individual-
ized dosing during ENDURANCE.
Similar to BCVA, mean CRT remained relatively stable
during ENDURANCEwith individualized IAI retreatment
(Figure 3). Gross diabetic retinopathy severity levels were
similar at ENDURANCE baseline compared to M12
(Table 2); however, 2 patients developed new neovascula-
rization, progressing from nonproliferative to proliferative
DR: 1 patient at week 24 after receiving no IAIs during
ENDURANCE and 1 patient at week 52, 24 weeks after
their last IAI.VOL. 173 AFLIBERCEPT IN DME: ENDU RETREATMENT FREQUENCY: During ENDURANCE,
18 (30%) patients did not have CR-DME and therefore
did not require additional IAIs to maintain the gains
achieved during VISTA DME. The remaining 42 (70%)
patients received >_1 IAI during ENDURANCE, with 21
(35%) patients receiving <6 IAIs, and 6 (10%) patients
receiving between 12–14 IAIs (Figure 4). Overall, the
weighted mean number of IAIs through M12 was 4.5 and
the mean number of IAIs during ENDURANCE was
similar between each of the original VISTA DME random-
ized arms, with no significant differences in injection fre-
quency during ENDURANCE between patients who
were originally randomized to Q4, Q8, or laser in VISTA
DME (P ¼ .19). Among patients who met IAI retreatment
criteria during ENDURANCE, the mean number of IAIs
through M12 was 6.0.
Among patients who completed >_3 months of ENDUR-
ANCE (n ¼ 57), the interval between visits was extended
at this earliest possible point for 15 (26%) patients. Among
patients who completed M12, 15 (28%) patients were
maximally extended to a 12-week interval, while 26
(48%) were at a 4-week interval and 13 (24%) were at
an 8-week interval. Cumulatively, 38 (67%) patients met
stability criteria at 3 consecutive visits and were extended
beyond a 4-week visit interval at least once, while 19
(33%) patients never met criteria for extension of their
visit interval.
In total, 37 (62%) patients met criteria for macular laser
at a mean of 19.5 weeks (range 12–40 weeks). Among those
who met macular laser criteria, 25 (68%) received macular
laser, with a mean of 1.7 macular laser sessions adminis-
tered per patient through M12. The remaining 12 patients
did not receive macular laser because of the lack of treat-
able microaneurysms (n ¼ 5), treatment being too close
to the FAZ (n¼ 5), significant macular ischemia involving
the FAZ (n ¼ 1), and patient preference (n ¼ 1). Among59RANCE EXTENSION STUDY
FIGURE 3. Mean change in central retinal thickness (CRT) during VISTADME (Study of Intravitreal Aflibercept Injection in Pa-
tients With Diabetic Macular Edema) and ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treat-
ment of DME in Subjects Who Completed the VISTA DME Trial) extension study. IAI indicates patients who were randomized to
intravitreal aflibercept injections during VISTADME, combining patients in both the monthly aflibercept arm and every other month
aflibercept arm after 5 monthly loading doses. Laser indicates patients who were randomized to the macular laser photocoagulation
arm during VISTA DME.
TABLE 2. Diabetic Retinopathy Severity During the
ENDURANCE Extension Study
Diabetic Retinopathy Severity Baseline Month 12
Mild to moderate NPDR, n (%) 43 (72) 37 (69)
Severe NPDR, n (%) 3 (5) 3 (6)
PDR, n (%) 14 (23) 14 (26)
NPDR¼ nonproliferative diabetic retinopathy; PDR¼ proliferative
diabetic retinopathy.those who received macular laser, a mean of 7.7 IAIs were
administered through M12, with an annualized 8.2 and 7.8
mean injections before and after macular laser, respectively
(P ¼ .68).
 SAFETY: Overall, as-needed IAIs during ENDURANCE
were well tolerated with no new safety signals. AEs and
SAEs are summarized in Table 3. The most common ocular
AEs during ENDURANCE were progressive diabetic reti-
nopathy (n ¼ 7, 12%) and worsening cataract (n ¼ 6,
10%). There were no cases of endophthalmitis or intraocular
inflammation throughM12 of ENDURANCE.Twomyocar-
dial infarctions were reported in addition to 5 other SAEs re-
ported to be related to cardiac and vascular complications,
including worsening coronary artery disease (n ¼ 2),
arrhythmia (n¼ 1), hypotension (n ¼ 1), and hypertension
(n¼ 1).DISCUSSION
THE ENDURANCE EXTENSION STUDY SHOWS THAT THE VI-
sual and anatomic gains achieved with IAI fixed dosing60 AMERICAN JOURNAL OFduring VISTA DME can be maintained with a substan-
tially reduced treatment frequency after initially intensive
anti-VEGF therapy. The VA stability observed during
ENDURANCE with <1.5 mean letter fluctuation from
baseline at all time points shows the efficacy of the individ-
ualized regimen for maintaining visual outcomes in this
study with a mean of 4.5 IAIs through M12. During
ENDURANCE, 30% of patients had no clinically relevant
disease activity to warrant DME treatment, suggesting that
while ongoing disease monitoring is needed to identify
those requiring treatment, some patients may be able to
stop treatment at least through 12 months of follow-up.
These findings of a reduced treatment burden upon tran-
sitioning to an individualized retreatment approach are
consistent with studies using ranibizumab for DME treat-
ment. In the OLE after completion of the 3-year RISE
(Ranibizumab Injection in Subjects With Clinically Sig-
nificant Macular Edema With Center Involvement Sec-
ondary to Diabetes Mellitus)/RIDE (Ranibizumab
Injection in Subjects With Clinically Significant Macular
Edema With Center Involvement Secondary to Diabetes
Mellitus) study program, 24.2% of patients received no
additional ranibizumab injections and 4.5 mean ranibizu-
mab injections were delivered during a mean of
14.1 months of follow-up.13
Importantly, however, 70% of patients did have CR-
DME during ENDURANCE, which essentially represented
the fourth year of IAI treatment since enrollment of these
patients into VISTA DME, indicating that the underlying
disease process continues to be active in a substantial pro-
portion of patients. Apparently disparate results to the find-
ings of the OLE and ENDURANCE extension studies have
been reported in the 4- and 5-year DRCR.Net Protocol I
data, in which patients in the ranibizumab arms required
few additional injections (median 0–1) to maintain VA
gains achieved with earlier, more frequent dosing.12 TheJANUARY 2017OPHTHALMOLOGY
TABLE 3. Ocular and Serious Systemic Adverse Events
During the ENDURANCE Extension Study
Ocular AEs
Total AEs, n (%) 30 (50)
Progressive diabetic retinopathy 7 (12)
Worsening cataract 6 (10)
Ocular sensitivity 5 (8)
Vitreous hemorrhage 4 (7)
Decreased vision 4 (7)
Floaters 3 (5)
Optic nerve pallor 1 (2)
Serious SAEs
Total SAEs, n (%) 22 (37)
Cardiac and vascular complications 7 (12)
Bacterial and viral infections 5 (8)
Pulmonary complications 3 (5)
Gastrointestinal complications 3 (5)
Psychiatric complications 2 (3)
Renal complications 1 (2)
Ischemic stroke 1 (2)
AE ¼ adverse event; SAE ¼ systemic adverse event.
FIGURE 4. Distribution of as-needed intravitreal aflibercept
injections during ENDURANCE (Long-Term Efficacy and
Safety of Intravitreal Aflibercept for the Treatment of DME
in Subjects Who Completed the VISTA DME Trial) extension
study.reason(s) for such differences are unknown and may be
multifactorial. One clear distinction between the studies
pertains to the distinct retreatment criteria; in particular,
both the OLE and ENDURANCE extension studies deliv-
ered retreatment in the presence of DME, while the DRCR.
Net algorithm allowed observation of persistent DME
without continued injection therapy if protocol-defined
clinical stability was achieved.
Macular laser photocoagulation has been validated for
the treatment of DME17 and continues to play an impor-
tant role in the management DME in many recent and
ongoing phase III trials.14 ENDURANCE evaluated the
role of macular laser in reducing IAI frequency among
eyes receiving >_2 IAIs within 24 weeks. Through M12,VOL. 173 AFLIBERCEPT IN DME: ENDU62% of patients met macular laser criteria and IAI
retreatment frequency was not significantly decreased after
macular laser application, reducing the annualized mean
IAI frequency from 8.2 to 7.8. Possibly, given that
ENDURANCE represents at least the fourth year of treat-
ment for these DME patients, the benefit of macular laser
toward reducing injection burden was not realized because
the laser was applied too late in the disease course. In addi-
tion, the value of macular laser toward reducing treatment
burden may only become apparent with longer clinical
follow-up. For example, among the ranibizumab arms
within DRCR.Net Protocol I, no substantial difference in
treatment burden was identified through year 1, while the
5-year follow-up data suggested that eyes receiving prompt
macular laser at the beginning of the trial required fewer
ranibizumab injections (median 13) compared to those
randomized to deferred macular laser (median 17) to
achieve similar visual outcomes.12
The systemic safety of anti-VEGF medications is a
potentially clinically relevant issue. Published meta-
analyses and large cohort studies18–21 conflict regarding
the potential systemic impact of anti-VEGF agents admin-
istered intravitreally and suggest that high-risk patients
with higher levels of drug exposure may correlate with
increased risk.19 While the current 12-month study was
not powered to detect small systemic safety signals nor
determine causality, 2 myocardial infarctions were reported
along with 5 additional systemic adverse events related to
cardiac and vascular complications. More data and
continued scrutiny of systemic safety signals after intravi-
treal drug delivery are warranted.
One key challenge of prospective trials evaluating DME
management is the standardization of retreatment parame-
ters. In the context of neovascular age-related macular
degeneration, even small amounts of macular edema appear
to be clinically relevant and damaging to ultimate VA,22
necessitating ongoing aggressive treatment.23 In compari-
son, similar amounts of fluid may be more tolerated in
DME, and many as-needed retreatment protocols have
tolerated a limited amount of DME without demanding
more aggressive treatment. The ENDURANCE retreatment
criteria were intentionally created to allow physicians to use
their clinical judgement as to the necessity of retreatment
based on a combination of factors. While this simulates a
real-world IAI retreatment approach, by necessity it allows
for a potentially greater degree of variability in determining
retreatment attributable to investigator discretion.
The other key limitation of the ENDURANCE exten-
sion study is that only a proportion of the patients who
completed VISTA DME were offered enrollment and
only 60 enrolled; while these patients were not preselected
in any way and had baseline characteristics that were over-
all consistent with the benefits achieved and the time
elapsed during VISTA DME, these patients and their out-
comes may or may not represent the entire VISTA DME
patient population. The strengths of this study are its61RANCE EXTENSION STUDY
prospective design involving well-defined patient cohorts
and high protocol compliance.
The results of the ENDURANCE extension study pro-
vide insight into the clinical application of IAIs in the
long-term management of DME. These findings provide62 AMERICAN JOURNAL OFfurther support for a DME treatment paradigm of initial,
intensive anti-VEGF therapy followed by a substantial
reduction in visit and treatment burden using an individu-
alized retreatment approach based on evidence of clinically
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